6699 (6699) Fair Value & Analysis

Healthcare · Market cap HK$12.2B

6 6699 6699 · HK

PriceHK$71.40

Fair ValueHK$20.78

Upside-70.9%

Quality70/100

Watch 6699 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$16.72 – HK$24.84

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −0.3% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$51.47 – HK$92.86 · fair‑value band HK$16.72 – HK$24.84 · the HK$71.40 price screens above the HK$20.78 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6699 (6699) currently trades at HK$71.40, while our model-based Fair Value estimate is HK$20.78 — implying the stock looks roughly 70.9% overvalued today. We read business quality at 70/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 6699 generated revenue of HK$370M at a net margin of 7.7%. Revenue grew 41.6% year over year. It earns a return on equity of 5.4%. The balance sheet holds a net cash position of HK$775M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$370M

Revenue growth (YoY) +41.6%

Net margin 7.7%

Return on equity 5.4%

Free cash flow HK$523M FY2025

P/E ratio 53.7

More key figures

Operating margin 9.6%

EPS (TTM) HK$0.0900

Dividend yield 0.1%

EPS growth (YoY) +60.2%

Net cash HK$775M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6699 reported revenue of HK$2.6B in FY2025 versus HK$1.3B in FY2021, a compound +19.5%/yr. Reported net income was HK$199M in FY2025, compounding −8.6%/yr from FY2021.

Revenue +19.5%/yr

FY21 HK$1.3B

FY22 HK$1.3B

FY23 HK$1.5B

FY24 HK$2.0B

FY25 HK$2.6B

Net income −8.6%/yr

FY21 HK$286M

FY22 HK$214M

FY23 HK$53.5M

FY24 HK$88.4M

FY25 HK$199M

Is 6699 fairly valued? → Check now

Similar stocks

6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$422.06	$165.35	-61%
EssilorLuxottica Société anonyme ESLOF	$205.86	$114.90	-44%
HOYA Corporation HOCPY	$178.46	$103.27	-42%
Medline Inc MDLN	$36.54	$30.66	-16%
Becton, Dickinson and Company BDX	$147.79	$124.26	-16%
Alcon Inc ALC	$65.18	$44.21	-32%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6699 (6699) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$20.78 versus a price of HK$71.40 — about −71% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 6699?

Our model-based fair value for 6699 is HK$20.78 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$71.40.

What is the quality score of 6699?

6699 has a Quality Score of 70/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6699 (6699)?

6699 reported trailing-twelve-month revenue of about HK$370M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6699?

The net profit margin of 6699 is about 7.7%, meaning it keeps roughly 7.7% of revenue as net income. Based on the latest reported figures.

Does 6699 pay a dividend?

6699 currently shows a dividend yield of about 0.09% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.